ADVERTISEMENT
ADVERTISEMENT

Bio-Rad Expedites Disease Biomarker Discovery and Drug Development with the Launch of Bio-Plex Pro Human Cytokine Screening Panel

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the Bio-Plex Pro Human Cytokine Screening Panel, the first validated high-performance multiplex assay on the market. The panel can identify and quantify 48 different analytes linked to heart disease, autoimmunity and allergy, cancer, and many other conditions.

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the Bio-Plex Pro Human Cytokine Screening Panel, the first validated high-performance multiplex assay on the market. The panel can identify and quantify 48 different analytes linked to heart disease, autoimmunity and allergy, cancer, and many other conditions.

The Bio-Plex Pro Human Cytokine Screening Panel has been validated to deliver more accurate data points within assay range than similar multiplex assays on the market,” said Ivan Huang, Bio-Rad Global Product Manager, Bio-Plex. “The ability to accurately probe both endogenous and diseased/treated samples with a single assay across a broad range of targets gives researchers tremendous insight and enables them to make actionable decisions in terms of biomarker discovery and drug development.”

To understand complex biological networks, disease states, and treatment effects, biopharma and academic researchers need to simultaneously interrogate many biomarkers present in human samples. The Bio-Plex...

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
ADVERTISEMENT